DAEWOONG PHARMACEUTICAL
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Daewoong Pharmaceutical Unveils 'Innovative Drug Delivery Technologies' in Milan--From World's First Microneedle Therapy to Once-a-Month Obesity Treatment 2024-10-10 06:16
Daewoong Pharmaceutical Receives Positive Recommendation from IDMC to Continue Developing its First-in-Class PRS Inhibitor, Bersiporocin 2024-07-29 20:00
Novosis Putty Sets the Stage for U.S. Market Success with Promising Clinical Results 2024-05-14 20:00
Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA 2023-11-28 08:00
Daewoong Pharmaceutical Initiates Global Export of 'Novel Drug' Launching 'Fexuprazan' in the Philippines 2023-08-16 13:00
Daewoong Pharmaceutical submits a new drug application for Fexuprazan in China challenging the world's largest market for anti-ulcer drugs 2023-07-31 08:00
Daewoong Pharmaceutical has obtained approval for SGLT2i + metformin combination drug Envlomet 2023-07-19 08:52
Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic in EMBO Molecular Medicine 2023-05-26 06:00
Daewoong Pharmaceutical Presents New Clinical Data of Fexuprazan at Digestive Disease Week 2023 2023-05-19 20:00
Daewoong Pharmaceutical announces a Global License Agreement for DWP213388, a new drug candidate for autoimmune disease with Vitalli Bio 2023-04-28 08:58
Daewoong Pharmaceutical Announce Publication of Phase 3 Study of 'Envlo', a New Treatment for Diabetes, in the International SCIE Journal 2023-04-24 14:53
Daewoong Pharmaceutical and Sygnature Discovery announce drug discovery research collaboration 2023-04-18 17:16
Daewoong Pharmaceutical's Envlo to enter the global market in full swing with filing for product license in three ASEAN countries 2023-03-22 21:20
Daewoong Pharmaceutical Reaches Sales of KRW 1.16 Trillion in 2022, Fexuclue Leads The Highest Revenue 2023-02-20 12:29
Daewoong Pharmaceutical begins the first administration of the Bersiporocin, new treatment for idiopathic pulmonary fibrosis, as Phase II clinical trial 2023-02-06 13:00
Daewoong enters exclusive licensing agreement with CS Pharmaceuticals for Bersiporocin in Idiopathic Pulmonary Fibrosis in the Greater China Region 2023-01-31 14:43
Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue in 11 countries, only 1 year after approval in Korea 2023-01-26 09:14
Daewoong Pharmaceutical announces success in developing a new antidiabetic medication and its aims to enter the market in over 50 countries by 2030 2022-12-06 20:00
Daewoong Pharmaceutical Surpasses KRW 300 Billion in Q3 Revenue as Nabota Sales Grew by 93%, Leading Overall Growth in Revenue 2022-11-15 20:00
Daewoong Pharmaceutical Presents Phase 3 Clinical Trial Results of New Diabetes Treatment 'Enavogliflozin' and Roadmap to Enter 50 Countries by 2030 2022-11-02 09:00
1 2 3